Michael Ellenbogen kindly sent me a report detailing ongoing drug clinical trials for Alzheimer's disease.  Here are parts of the summary:

New BIO Report: More Progress Needed in Innovation of Alzheimer’s Disease Therapeutics

Poor R&D Success Rates: Clinical development success for disease-modifying drug programs for Alzheimer’s has been difficult in late-stage trials, with no disease-modifying drugs moving beyond Phase III to FDA filing. Since 2008, a total of 87 clinical-stage disease-modifying programs have been suspended.

• Growing & Diverse R&D Pipeline: There are 74 clinical-stage programs with disease-modifying potential in Alzheimer’s disease. The drug candidates in these programs are attempting to stop, prevent, or slow the progression of Alzheimer’s disease using 10 different strategies involving 30 distinct molecular targets. Small biotech companies account for more than three-fourths of these clinical programs.

Here is a list of the ten strategies for treating Alzheimer's disease and the number of clinical trials for each:

Targeting the Amyloid Pathway (33)

Targeting the Tau Pathway (12)

Regeneration of Neurons (12)

Reversing Neuroinflammation (7)

Targeting Epigenetic Modification (3)

Targeting Metabolic Pathways (2)

Targeting Glucocorticoids (2)

Targeting Oxidative Stress (1)

Targeting Infectious Agents (1)

Targeting the Epichaperon (1)

Here is some information on preclinical trials:

Preclinical Pipeline To predict what may enter the clinical pipeline soon, we examined novel preclinical disease-modifying Alzheimer’s disease programs in the Biomedtracker databases and recently published literature. We found that 23 of the 102 preclinical programs listed had unique targets not currently in the clinic, indicating further advances may be on the horizon. The mechanistic strategies are quite varied within the 23 new targets, including caspases, different growth receptors, inflammation factors, kinases, and modified blood proteins that may restore or protect neuronal function. Sixteen of the preclinical programs had unknown mechanisms

You may want to have a look at non-drug therapies.

  Montpelier France, and YANKEE EYE CLINIC, EAGAN, MINNESOTA

• Alzheimer Disease

• Device: Photobiomodulation REGEnLIFE RGn530 device
• Device: SHAM REGEnLIFE RGn530 device

• Montpellier University Hospital, Gui de Chauliac
  Montpellier, France

• Diabetic Retinopathy (DR)
• Age-related Macular Degeneration (AMD)
• Mid-peripheral Drusen Formation
• Diabetic Macular Edema (DME)

• Behavioral: Photobiomodulation
• Behavioral: Ketogenic diet

• Yankee Eye Clinic
  Eagan, Minnesota, United States

Vie Light announced a clinical trial on June 6, 2019

here are the results from the first trial, which had five people:

Another source of information on clinical trials for Alzheimer's disease in 2019.

https://www.sciencedirect.com/science/article/pii/S2352873719300290

There are 2150 clinical trials worldwide for Alzheimers.  Use www.clinicaltrials.gov

 Check here for Clinical trials in your area

https://clinicaltrials.gov/ct2/results?cond=Alzheimer+Disease&term=&cntry=&state=&city=&dist=

CLINICALTRIALS.GOV

23 light therapy studies for Alzheimers are currently recruiting

 64 (SIXTY-FOUR) Studies for LIGHT THERAPY ALZHEIMER DISEASE

 https://clinicaltrials.gov/ct2/results?cond=Alzheimer+Disease&term=light+therapy&cntry=&state=&city=&dist=&Search=Search

Status

Recruitment :

• Not yet recruiting
• Recruiting
• Enrolling by invitation
• Active, not recruiting
• Suspended
• Terminated
• Completed
• Withdrawn
• Unknown status†

Expanded Access :

Eligibility Criteria

Age :
yearsORAge Group :

Child (birth–17)
Adult (18–64)
Older Adult (65+)

Sex :

All
Female
Male

Accepts Healthy Volunteers

Study Type

Study Results

Study Phase

Funder Type

Study Documents

• Alzheimer's Disease

• Other: Luxtherapy

• Hôpital Charles Foix
  Ivry-sur-Seine, France

• Alzheimer's Disease
• Dementia

• Device: high-intensity light therapy

• John Umstead Hospital
  Butner, North Carolina, United States

• Alzheimer's Disease

• Device: Morning Simulated Sunlight
• Device: Non-therapeutic Red Light

• Botsford Continuing Care
  Farmington Hills, Michigan, United States

• Alzheimer Disease
• Diabetes Mellitus, Type 2

• Device: Tailored Lighting Intervention

• Rensselaer Polytechnic Institute
  Troy, New York, United States

• Alzheimer Disease

• Other: Deep brain stimulation

• Uni-Klinik Köln AöR
  Cologne, North Rhine Westphalia, Germany

• Alzheimer Disease
• Mild Cognitive Impairment
• Dementia
• (and 3 more...)

• Device: Combination of 40Hz light and cognitive therapy (ALZLIFE)

• Andrey Vyshedskiy
  Miami, Florida, United States

• Mild Cognitive Impairment
• Alzheimer Disease
• Type2 Diabetes

• Device: Tailored Lighting Intervention

• Mount Sinai School of Medicine
  New York, New York, United States

• Alzheimer's Disease

• Device: Erchonia ALS Laser
• Device: Placebo Laser

• Pruebas Clinicas
  Zapopan, Jalisco, Mexico
• Neocemod
  La Plazuela, Pocitos AGS, Mexico

• Sleep Initiation and Maintenance Disorders

• Device: Bright light
• Device: Control

• VA Palo Alto Health Care System
  Palo Alto, California, United States

• Alzheimer Disease

• Device: Vielight Neuro Gamma
• Other: Sham Vielight Neuro Gamma

• VA Health Care System
  San Francisco, California, United States
• UCSF Memory and Aging Center
  San Francisco, California, United States

• Copyright
• Privacy
• Accessibility
• Viewers and Players
• Freedom of Information Act
• USA.gov

postmortum Question 1: A diagnosis of AD during life could only be “probable”, whereas a “definite” diagnosis required post-mortem histopathological confirmation. 

Question: Is this not confusing for the patient and his/her caregiver? Them why continue using The Diagnosis Alzheimer''s Disease??? 

Specialists from Temple University discovered that there is a connection between the movement of Alzheimer's and some useless changes in calcium transport by the cell's mitochondria, which contains chemicals in charge of creating vitality.

Now researcher are working on remodeling of calcium transport by mitochondria

https://www.myhealthyclick.com/temple-university-researchers-discover-new-cellular-target-to-treat-alzheimers/

Thank you Bob. Its about time the media started to publish information about this juggernaut of a breakthrough.

When Alois Alzheimer defined the disease, he warned the medical community, do not be tempted to think that amyloid plaques and neurofibrillary (tau) tangles are the cause of this disease, they are but symptoms.

Since its discovery in1906,  it only took us 113 years to find out he was right.